Novel biomarkers of overactive bladder syndrome

Ginekol Pol. 2017;88(10):568-573. doi: 10.5603/GP.a2017.0102.

Abstract

The social aspect of overactive bladder syndrome (OAB) and the lack of objective diagnostic methods for this syndrome have spurred research into its potential biomarkers which can constitute useful diagnostic tools, while also allowing the evaluation of the intensity of clinical symptoms and the efficacy of implemented pharmacotherapy in OAB patients. Due to the complex etiopathogenesis of this syndrome, the researchers are seeking biomarkers connected with inflammation or nerve growth. The aim of this review was to analyse the latest literature data regarding potential biomarkers in OAB. The most promising opportunities are connected with the diagnostic use of the nerve growth factor (NGF), the brain derived neurotrophic factor (BDNF), C-reactive protein (CRP), prostaglandins and cytokines. Despite the most promising results to date having been obtained with regards to neurotrophic factors, it seems that, at the moment, none of these meets the criteria for becoming an isolated OAB marker. It is also suggested that the combined use of several biomarkers will facilitate obtaining the appropriate level of specificity and selectivity to allow their use in clinical practice.

Keywords: biomarker; diagnosis; overactive bladder.

Publication types

  • Review

MeSH terms

  • Biomarkers / urine*
  • Brain-Derived Neurotrophic Factor / urine
  • C-Reactive Protein / urine
  • Female
  • Humans
  • Nerve Growth Factor / urine
  • Urinary Bladder, Overactive / diagnosis*
  • Urinary Bladder, Overactive / urine

Substances

  • Biomarkers
  • Brain-Derived Neurotrophic Factor
  • NGF protein, human
  • BDNF protein, human
  • C-Reactive Protein
  • Nerve Growth Factor